Breakthrough T1D, Formerly JDRF, Expresses Disappointment in FDA Advisory Committee Recommendation Regarding Sotagliflozin
October 31, 2024
October 31, 2024
NEW YORK, Oct. 31 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, issued the following news release:
Breakthrough T1D, formerly JDRF, is disappointed to learn that a U.S. Food and Drug Administration (FDA) advisory committee did not recommend approval of sotagliflozin for people with T1D and chronic kidney disease.
There remains a deep unmet need for therapies that improve health outcomes and quality of life for those wit . . .
Breakthrough T1D, formerly JDRF, is disappointed to learn that a U.S. Food and Drug Administration (FDA) advisory committee did not recommend approval of sotagliflozin for people with T1D and chronic kidney disease.
There remains a deep unmet need for therapies that improve health outcomes and quality of life for those wit . . .